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Abstract
Background: Although the etiology of preeclampsia is still unclear, recent work suggests that changes in
circulating angiogenic factors play a key role in its pathogenesis. In the trophoblast of women with preeclampsia,
hypoxia-inducible factor 1 alpha (HIF-1a) is over-expressed, and induces the expression of non-angiogenic factors
and inhibitors of trophoblast differentiation. This observation prompted the study of HIF-1a and its relation to
preeclampsia. It has been described that the C1772T (P582S) and G1790A (A588T) polymorphisms of the HIF1A
gene have significantly greater transcriptional activity, correlated with an increased expression of their proteins,
than the wild-type sequence. In this work, we studied whether either or both HIF1A variants contribute to
preeclampsia susceptibility.
Results: Genomic DNA was isolated from 150 preeclamptic and 105 healthy pregnant women. Exon 12 of the
HIF1A gene was amplified by PCR, and the genotypes of HIF1A were determined by DNA sequencing.
In preeclamptic women and controls, the frequencies of the T allele for C1772T were 4.3 vs. 4.8%, and the
frequencies of the A allele for G1790A were 0.0 vs. 0.5%, respectively. No significant differences were found
between groups.
Conclusion: The frequency of the C1772T and G1790A polymorphisms of the HIF1A gene is very low, and neither
polymorphism is associated with the development of preeclampsia in the Mexican population.
Background
Preeclampsia (PE), a systemic syndrome occurring in
pregnant women, is characterized by the new onset of
hypertension and proteinuria after 20 weeks of gestation
and prior to 48 h postpartum [1-3]. It is the most
important cause of morbidity and mortality in the
mother-fetus binomial, affecting 5 to 8% of pregnant
women worldwide. The actual percentage depends on
the population studied and the definition of preeclamp-
sia employed [4-6].
One of the main characteristics of PE is an inadequate
trophoblast invasion leading to an incomplete remodel-
ing of the spiral artery, a reduction in utero-placental
perfusion, and a state of placental hypoxia. It is
considered that this condition can trigger widespread
maternal endothelial dysfunction, and therefore the sys-
temic manifestation of PE [7,8].
HIF-1a is the major transducer of hypoxia signaling in
several tissues, including human placenta [9,10]. Several
studies suggest that hypoxia-inducible factor 1 alpha
(HIF-1a), and two of the numerous genes that it regu-
lates [11], soluble fms-like tyrosine kinase 1 (sFlT-1)
and soluble endoglin (sEng) [12,13], are over-expressed
in preeclamptic women and play a key role in the devel-
opment of PE [14-17].
It has been reported that a base change of C to T at
1772, or G to A at 1790 in exon 12 of the HIF1A gene
can increase the transcriptional activity of this gene
compared to the wild type isoform [18]. Several studies
have reported associations between these polymorph-
isms and different diseases in which alterations of HIF-a
and its target genes are implicated, such as diabetes,
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any medium, provided the original work is properly cited.coronary disease and cancer (renal cell carcinoma; head,
neck, colorectal, breast, and lung cancer) [19-22].
The aim of this study was to determine if there is an
association between the presence of C1772T and/or
G1790A polymorphisms and the development of PE in
the Mexican population.
Methods
Population
We conducted a prospective case-control study with
patients admitted to the Gynecology Hospital 4, Luis
Castelazo Ayala of Mexican Social Security Institute in
Mexico City. Patients were recruited from September
2008 to July 2010, including 105 healthy pregnant
women and 150 preeclamptic women. Among the latter
group, 29 patients had mild PE (MPE) and 121 severe
PE (SPE). 36 patients presented HELLP syndrome and
11 intrauterine growth restriction (IUGR).
The diagnosis of PE was made according to interna-
tional and Mexican Ministry of Health guidelines [1,3].
Criteria for MPE were as follows: blood pressure ≥ 140/
90 mm Hg persisting for at least 6 h, and proteinuria
≥300 mg/day after the 20th week of gestation. Criteria
for SPE were: blood pressure ≥ 160/110 mmHg persist-
ing for at least 6 h, and proteinuria ≥2 g/day after the
20th week of gestation. Additionally, at least one of the
following symptoms was present for SPE: headache,
visual disturbance, epigastric pain or pulmonary edema.
Criteria for HELLP syndrome were: thrombocytopenia
(≤100 000/μl), increase in lactic dehydrogenase (LDH)
(>600 U/l), aspartate aminotransferase and alanine ami-
notransferase levels (AST and ALT ≥70 U/l). IUGR was
determined by a birth weight below the 10th percentile
for gestational age. Women with term pregnancy and
without complications were recruited as controls.
Excluded from the study were women with chronic
hypertension, diabetes mellitus, gestational diabetes,
renal or autoimmune disease.
The information on maternal demographic character-
istics and family history was gathered from all subjects
by personal interview. The study was approved by the
Ethics Committee of the Hospital and by the Mexican
Ministry of Health. Informed consent was obtained
from all patients and controls.
Genotyping
Genomic DNA was isolated from the peripheral blood
leukocytes by using standard protocols. Polymerase
chain reaction (PCR) was performed to amplify the 178-
bp fragment of the exon 12 of the HIF1A human gene,
as previously reported [18], using the 5’-CAT GTA TTT
GCT GTT TTA AAG-3’ forward primer and 5’-GAG
TCT GCT GGA ATA CTG TAA CTG-3’ reverse pri-
mer. The mixture for PCR was in 30 μL, containing
200 ng template DNA, 0.2 mM of each dNTP, 0.5 μM
of each forward and reverse primer, 1.5 mM MgCl2,
0.5 U of Taq polymerase and 3 μLo f1 0 XP C Rb u f f e r .
The conditions for the PCR reaction were: denaturation
at 95°C for 5 min, followed by 35 cycles of denaturation
at 95°C for 30 sec, annealing at 61°C for 30 sec, exten-
sion at 70°C for 1 min, and a final extension at 72°C for
10 min. PCR products were purified and sequenced
using Big Dye Terminator kit (version 3.1) on an ABI
Prism
® 3100 Automated DNA sequencer according to
the manufacturer’s protocol (Applied Biosystems, Foster
City, CA).
Statistical analysis
We compared clinical characteristics between pree-
clamptic and control groups. Data are presented as the
mean ± SEM. Statistical significance between groups
was established with a one-way analysis of variance
(ANOVA), followed by the Turkey’s multiple compari-
son test or student-t test, as appropriate.
Differences in genotypic frequencies between the two
groups were tested for significance by using two by two
contingency tables and Fisher’s exact statistical test, and
the odds ratios were calculated using 95% confidence
intervals (CI). Data were analyzed using Graph Pad
Prism Software V.5.1.
Test for the Hardy-Weinberg equilibrium, which
revealed normal distribution of the population, was per-
formed by the c
2 test in http://www.oege.org.
The frequencies of genetic polymorphisms and the
prevalence of PE in Mexican population (reported as
7%) were used for statistical power calculation in
Quanto V.1.2.
P-values <0.05 were considered as statistically signifi-
cant. All statistical tests were two-tailed.
Results
We conducted a case-control study to determine
whether the presence of either of two single nucleotide
polymorphisms (SNP) of the HIF1A gene is associated
with the development of PE in Mexican population.
Table 1 shows the demographic and clinical character-
istics of cases and controls. The group of women with
PE showed a lower infant birth-weight, shorter gesta-
tion, and higher body mass index (BMI) compared to
the control group. There were also a higher percentage
of women with PE who smoked before pregnancy. All of
these differences were statically significant. There were
no differences in age and the frequency of primigravidas
between the two groups. The seventeen PE patients
(18%) who were multigravidas had a past history of PE.
The genotypic frequencies of C1772T and G1790A
polymorphisms of the HIF1A gene are presented in
Table 2. There were no significant differences in the
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None of the individuals presented the two polymorph-
isms, and those with either of the polymorphisms were
considered heterozygotes. In the group of cases with
C1772T polymorphism, 3 patients presented MPE and
10 SPE. Two of the latter also had IUGR and one had
HELLP syndrome. The G1790A polymorphism was only
observed in one women of the control group, also con-
sidered heterozygote. The genotype frequencies were in
agreement with the Hardy-Weinberg equilibrium.
Discussion
There is strong evidence that an imbalance between
angiogenic factors, such as vascular endothelial growth
factor (VEGF), placental growth factor, and factors inhi-
biting angiogenesis, such as sFlt1 and sEng, are closely
related to the pathogenesis of PE [16,17]. Since HIF-a is
the main regulator of the angiogenic/anti-angiogenic
factors that are over-expressed in women with PE, there
has been growing interest in the biology of the HIF-a
pathway and its role in human placenta development
[14].
Inv i t r ostudies have demonstrated that under both
normoxic and hypoxic conditions, the C1772T (P582S)
and G1790A (A588T) polymorphisms of the HIF1A
gene has a higher transcriptional activity, correlated
with an over-expression of the corresponding protein,
compared to the transcriptional activity and protein
expression of the wild-type sequence [18,23,24]. Further-
more, in various groups among different populations, an
association has been found between the presence of
these polymorphisms and the development of diseases
Table 1 Demographic and clinical characteristics of PE patients and the control group
Parameters Control PE P-value
N 105 150
Maternal Age (years) 27.7 ± 0.6 28.4 ± 0.6 NS
Smoking before pregnancy (%) 16.2 27.7 0.034
Primigravid (%) 37.9 36.9 NS
BMI (Kg/m
2) 28.9 ± 0.5 31.3 ± 0.8 0.011
Newborn weight (g) 2991.0 ± 63.1 2177.0 ± 74.6 < 0.001
GAD (weeks) 38.2 ± 0.2 34.8 ± 0.3 < 0.001
MPE SPE
SBP (mmHg) 114.1 ± 0.7 137.7 ± 1.9 155.0 ± 1.4 < 0.001
♦
DBP (mmHg) 73.3 ± 0.6 89.7 ± 1.3 100.9 ± 1.0 < 0.001
♦
Proteinuria (mg/24 h) ND 443.6 ± 63.5 2482.0 ± 377.4 < 0.001
♦♦
Values are the mean ± SEM. PE, preeclampsia; BMI, body mass index; GAD, gestational age at delivery; MPE, mild preeclampsia; SPE, severe preeclampsia; SBP,
systolic blood pressure; DBP, diastolic blood pressure; ND: not determined but negative using dipstick test. P values were calculated between the control and
preeclampsia group. NS, non significant.
♦ Control vs. MPE and SPE; MPE vs. SPE.
♦♦ MPE vs. SPE.
Table 2 Genotype and allele frequencies of the C1772T and the G1790A polymorphisms of the HIF1A gene in PE
patients and the control group
Nucleotide Amino acids Genotypes PE (%) Control (%) P-value OR (95% CI)
C1772T Pro582 CC 137 (91.3) 95 (90.5)
Ser582 CT 13 (8.7) 10 (9.5)
TT 0 (0.0) 0 (0.0)
CT + TT 13 (8.7) 10 (9.5) 0.203 * 0.485 (0.178-1.067)
Allele
C 287 (95.7) 200 (95.2) 0.831 0.906 (0.389-2.107)
T 13 (4.3) 10 (4.8)
Genotypes
G1790A Ala588 GG 150 (100.0) 104 (99.3)
Thr588 GA 0 (0.0) 1 (0.7)
AA 0 (0.0) 0 (0.0)
GA + AA 0 (0.0) 1 (0.7) 0.412 ** 0.232 (0.009-5.737)
Allele
G 300 (100.0) 209 (99.5) 0.411 0.232 (0.009-5.737)
A 0 (0.0) 1 (0.5)
PE, preeclampsia; OR, odds ratio; CI, confidence intervals. * Calculations were performed CC vs. CT + TT. ** Calculations were performed GG vs. GA + AA.
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cancer, diabetes and coronary disease [18-22].
In this study we determined the frequency of the
C1772T and G1790A polymorphisms of the HIF1A gene
and its possible correlation with PE risk in Mexican
population.
Analyzing the clinical and demographic characteristic of
our population (Table 1), we did not find a significant dif-
ference in age and parity between PE patients and women
with normal pregnancies. However, it has been reported
that women ≥ 40 years old have twice the risk of PE,
whether they were primiparous or multiparous, and that
as of the age of 34 the risk increases by 30% for each addi-
tional year. Nulliparous women have triple the risk of
developing PE, especially in young women (≤20 years old)
[25,26]. It is likely that the lack of significant differences
between our study groups in relation to risk for PE is due
to the age range of women included in the study.
Cigarette smoke exposure is associated with many
adverse effects in pregnancy, such as preterm labor, pre-
term premature rupture of membranes, placental abrup-
tion and IUGR. Paradoxically, smoking has been
associated with a decreased risk of PE. Several studies
argue that it has a protective effect if women continue to
smoke during pregnancy, and that contrarily, the protec-
tive effect is lost if the mother stops smoking [27,28]. In
our study, the percentage of smokers in the PE group
was higher compared with the control group, a difference
that was statistically significant (P = 0.034, OR = 1.984).
According to the questionnaires applied to patients, in all
cases the women stopped smoking before pregnancy.
Thus, the lack of protective effect under these circum-
stances is in agreement with the reported data.
With regard to body mass index, several studies sug-
gest that obese women have twice the risk of developing
PE, compared to women with normal BMI (20 -25).
Women with BMI >35 before pregnancy had over four
times the risk of PE [29]. The PE group had an average
BMI of 31, classified as obese type I, which was statisti-
cally different with regard to the BMI of the control
group.
There were also significant differences between the
two groups in terms of gestational age at delivery
(GAD) and newborn weight. 59% of women of the pree-
clamptic group delivered before 34 weeks of gestation, a
proportion that was higher among women with SPE
(63%) than MPE (41%). The tendency to an early deliv-
ery is due to the fact that PE is characterized by pro-
gressive deterioration in both maternal and fetal
conditions. For this reason, studies and clinical practice
indicate that after 34 weeks, the risk of continuing the
pregnancy is greater than the benefit, resulting in the
decision to terminate the pregnancy and the consequent
low weight of newborns. Additionally, PE can be
complicated with IUGR (10-25%). With this condition,
the physiological condition of the fetus determines
whether the pregnancy is continued or terminated [2].
PE is a heterogeneous disease, and therefore the differ-
ences between these factors depend on the individual
condition of each patient.
The genetic analysis of HIF polymorphisms between
the patients with PE and women with normal pregnan-
cies indicates that there are no significant differences in
terms of the distribution of C1772T and G1790A geno-
types and alleles (Table 2). For the 1772T allele, we
found frequencies similar to those reported for other
populations, such as Japan, Finland, Korea and China
[18,21,22,30-32]. The frequency of homozygous for the
Ta l l e l ei sv e r yl o w( 0 . 0 1 0 - 0 . 0 3 1 ) .I ns o m ep o p u l a t i o n s ,
like ours, the homozygous has not been found, which
m a yb ed u et oi t sl o wf r e q u e n c yp e rs ei nt h eM e x i c a n
population and/or the size of the sample analyzed.
In our population the frequency of the 1790A allele
was 0.005. This value is low compared to other popula-
tions (0.015 - 0.047). Indeed, the homozygote for the A
allele is very rare worldwide, and has only been reported
in Japanese and Korean populations [19,21].
There is an ethnicity-related variation in the distribu-
tion of C1772T and G1790A polymorphisms, as
reflected by studies of its association with particular dis-
eases in different populations [21,33].
In a study of both these polymorphisms and their
association with the development of PE in a Finnish
population [30], the frequency of the C1772T poly-
morphism was similar to that found in our study. Con-
trarily, our results show that the frequency of the
G1790A variant was lower than in the Finnish popula-
tion. Nevertheless, in neither the Finnish study nor in
our own, any association was found between the pre-
sence of these polymorphisms and the development
of PE.
T ot h eb e s to fo u rk n o w l e d g e ,t h eF i n n i s hs t u d ya n d
the current contribution are the only ones to evaluate
the frequency of the P582S and A588T polymorphisms
of HIF1A gene in patients with PE. Therefore, the pre-
sent study represents the first contribution from a Latin
American population. One limitation of this study is the
low statistical power; as t h es a m p l es i z ep r o v i d e sa
power less than the 50% under a dominant model. On
the one hand, the sample size should be increased, how-
ever, from our point of view, due to the insignificant
statistical difference observed between the study groups,
mainly for the variant P582S, these results would not
change if a larger number of patients were included in
each study group.
The inability to develop satisfactory prevention and
clinical prediction strategies for PE has led to various
focuses of investigation. Since previous reports have
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are strongly related to the pathogenesis of PE, one of
the approaches has been to attempt to establish a pre-
disposition to this disease in relation to genes that are
involved in the angiogenesis pathway. The result of
association studies between PE and different angiogenic
genes, such as VEGF, FLT and ENG, are inconsistent
[34-37]. Hence, further studies are necessary to deter-
mine whether these polymorphisms and their proteins
play a key role in the development of PE.
Conclusion
In the Mexican population, C1772T and G1790A poly-
morphisms of the HIF1A gene are not associated with
the development of PE.
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